GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
This article was originally published in The Pink Sheet Daily
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.
You may also be interested in...
Can GSK Market Breo Ellipta Dosing Advantage Without Adherence Advantage?
After successful advisory panel – at least for adult asthma indication – Breo Ellipta seems headed for an expanded label, but GSK is still struggling to find some clinical differentiation from its aging twice-daily Advair.
Breo Ellipta’s Adolescent Data Could Be Highest Hurdle For Asthma Claim
FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisors will cast separate votes March 19 on GSK’s ICS/LABA combo for patients 12-17 and for adults 18 and older.
GSK’s Breo Ellipta: FDA Panel To Weigh Large Safety Study For Asthma Claim
LABA safety issues may come to haunt GlaxoSmithKline as FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees will focus on the combination’s product’s safety database and whether an outcomes study is needed for approval in asthma.